Aclidinium Bromide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314208

CAS#: 320345-99-1

Description: Aclidinium bromide is a long-acting anticholinergic bronchodilator approved by the FDA in 2012 for use in the management of chronic obstructive pulmonary disease (COPD) which includes chronic bronchitis and emphysema. It is not however used for acute exacerbations. Aclidinium bromide is an inhalation powder promoted by Forest Pharmaceuticals in the US under the trade name Tudorza Pressair. It is also manufactured and marketed by Menarini Pharmaceuticals in the EU under the trade name Bretaris Genuair, in the UK as Eklira Genuair and in the Canada as Tudorza Genuair.


Price and Availability

Size
Price

5mg
Not available
50mg
Not available
500mg
Not available
5g
Ask price
50g
Ask price
Size
Price

10mg
Not available
100mg
Not available
1g
Ask price
10g
Ask price
100g
Ask price
Size
Price

25mg
Not available
200mg
Not available
2g
Ask price
20g
Ask price

Aclidinium Bromide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 314208
Name: Aclidinium Bromide
CAS#: 320345-99-1
Chemical Formula: C26H30BrNO4S2
Exact Mass: 563.07996
Molecular Weight: 564.5547
Elemental Analysis: C, 55.31; H, 5.36; Br, 14.15; N, 2.48; O, 11.34; S, 11.36


Synonym: trade name: Eklira Genuair; Tudorza Genuair; Bretaris Genuair

IUPAC/Chemical Name: [(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide

InChi Key: XLAKJQPTOJHYDR-QTQXQZBYSA-M

InChi Code: InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1

SMILES Code: O=C(O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)C(C4=CC=CS4)(O)C5=CC=CS5.[Br-]


Technical Data

Appearance:
solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother. 2013 Jul-Aug;47(7-8):1017-28. doi: 10.1345/aph.1S002. Epub 2013 Jun 4. Review. PubMed PMID: 23737515.

2: Cazzola M, Page CP, Matera MG. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. Review. PubMed PMID: 23566013.

3: Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther. 2013 Apr;30(4):354-68. doi: 10.1007/s12325-013-0019-2. Epub 2013 Apr 2. Review. PubMed PMID: 23553509.

4: Joos GF. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Drugs Today (Barc). 2012 Dec;48(12):757-63. doi: 10.1358/dot.2012.48.12.1885871. Review. PubMed PMID: 23243632.

5: Gupta V, Singh D. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2012 Dec;6(6):581-8. doi: 10.1586/ers.12.61. Review. PubMed PMID: 23234445.

6: Maltais F, Milot J. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2012 Dec;6(6):345-61. doi: 10.1177/1753465812463626. Epub 2012 Oct 17. Review. PubMed PMID: 23075544.

7: Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:457-66. doi: 10.2147/COPD.S15524. Epub 2011 Sep 16. Review. PubMed PMID: 22003291; PubMed Central PMCID: PMC3186744.

8: Alagha K, Bourdin A, Tummino C, Chanez P. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Ther Adv Respir Dis. 2011 Feb;5(1):19-28. doi: 10.1177/1753465810381546. Epub 2010 Sep 30. Review. Erratum in: Ther Adv Respir Dis. 2011 Apr;5(2):151. PubMed PMID: 20884687.

9: Sentellas S, Ramos I, Albertí J, Salvà M, Antón F, Miralpeix M, Beleta J, Gavaldà A. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39(5):283-90. doi: 10.1016/j.ejps.2010.01.004. Epub 2010 Jan 20. Review. PubMed PMID: 20093184.

10: Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs. 2009 May;10(5):482-90. Review. PubMed PMID: 19431081.